AMAG expands female focus with $700m Cord Blood buy
This article was originally published in Scrip
Executive Summary
AMAG Pharmaceuticals will increase its focus on women and maternal health with its $700m purchase of Cord Blood Registry (CBR) nine months after it acquired Lumara Health, the maker of pre-term labor drug Makena (hydroxyprogesterone caproate injection) for up to $1bn.